Recently, Chen et al. [192] have shown that the effects of TSA on HCC cells may be increased by pre-treatment with sorafenib, via the inhibition of RAF/MEK/ERK and NF-κB signaling pathways. Here, MAP2K7 is linked to hepatocellular carcinoma.